Systemic levels of 6-keto-prostaglandin F1 alpha following administration of inhaled aerosolized prostacyclin.
A case is described where systemic levels of prostacyclin metabolite were measured during inhaled aerosolized prostacyclin (IAP) therapy for severe hypoxaemia in a patient with the acute respiratory distress syndrome. Comparable levels of prostacyclin metabolite have been associated with a marked platelet aggregation defect in vitro. A platelet aggregation defect was also demonstrated in vivo in this patient. Haemodynamic and gas exchange data during the IAP therapy are described.
van Heerden
P V
PV
Department of Intensive Care, Sir Charles Gairdner Hospital, Perth, W.A.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000280:Administration, Inhalation; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D011464:Epoprostenol / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D000860:Hypoxia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects
D000959:Antihypertensive Agents; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol